Please ensure Javascript is enabled for purposes of website accessibility
Maxx Chatsko

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

arrow up shelves

Here's Why Repligen Stock Gained 12.8% in March

The bioprocess company was a rare bright spot for investors, although the worst is likely yet to come for the stock.


stock sliding chalkboard

Here's Why Zoetis Stock Fell 11.7% in March

The animal health company outperformed the S&P 500 last month. As of early April, it has also gained back most of its losses.


multiple lines down

Here's Why Tyson Foods Stock Dropped 14.7% in March

The food producer is an essential business, but it hasn't been spared by COVID-19.


stock down erased chalkboard

Here's Why Guardant Health Fell 20% in March

Growth stocks were among the worst performers during last month's correction.


stock down finger

Here's Why Viking Therapeutics Tumbled 20.9% in March

The small-cap pharma stock didn't stand a chance in the broader market volatility.

254 binoculars

2 Top U.S. Stocks to Watch in April

These two stocks can be used to gauge how the pharmaceutical industry and energy sector are faring during the coronavirus pandemic -- and what might be ahead.


410 binoculars kid

Stocks to Watch in April

An under-the-radar technology platform active in the fight against coronavirus and a leading electric utility are important stocks to keep an eye on this month.


046 dna model

My Top Biotech Stocks to Buy in the Market Crash

The worst may be yet to come for the stock market, but these biopharma companies have promising potential.


paper airplane down

Here's Why Deciphera Pharmaceuticals Lost 22.7% in March

Investors are concerned that an important regulatory deadline for the development-stage drug developer will be delayed because of the coronavirus pandemic.


stock down erased chalkboard

Here's Why Epizyme Lost 27.6% in March

Investors were looking forward to the drug company's transition to commercial operations, but the coronavirus pandemic could delay the maturation process.

businessman stock down

Here's Why Albemarle Stock Fell 31.1% in March

The world's largest lithium producer was bracing for a difficult 2020. Then the coronavirus pandemic hit.


stock down erased chalkboard

Here's Why Invitae Tumbled 32.9% in March

Growth stocks were among the most severely punished during the recent stock market crash.


multiple lines down

Here's Why Bloom Energy Fell 42.3% in March

The stock's compounding momentum proved no match for the coronavirus pandemic.


paper airplanes rising

Here's Why Fate Therapeutics Rose as Much as 18.7% Today

The cellular therapy developer announced an equity investment from and a partnership with Janssen, a subsidiary of Johnson & Johnson.


402 gold stock truck

Gold Stocks Soared Thursday as Investors Digested Sour Economic Data

Precious metals are thriving on the current economic upheaval.

arrow up shelves

Alliance Resource Partners Soared Today After Touching 20-Year Lows

Despite today's bounce, the coal producer faces an uncertain path ahead.


563 shocked phone

Here's Why Invitae Stock Is Swinging Wildly Today

The company announced the pricing of a public offering of common stock.


000 transmission lines

U.S. Coal-Fired Power Plants Stumbled Into 2020

Electricity generation from coal fell 35% in January 2020 from the year-ago period.


000 businessman celebrate sad

So Your Biotech Announced Positive Phase 3 Results? Celebrating Could be Premature

Success in clinical trials doesn't guarantee success on the market.


multiple lines down

Here's Why Alliance Resource Partners Stock Fell as Much as 13.9% Today

The company announced actions in response to the global economic slowdown caused by the coronavirus.